Cargando…

Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma

Stimulation of CD40 or Toll-Like Receptors (TLR) has potential for tumor immunotherapy. Combinations of CD40 and TLR stimulation can be synergistic, resulting in even stronger dendritic cell (DC) and CD8+ T cell responses. To evaluate such combinations, established B16F10 melanoma tumors were inject...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stone, Geoffrey W., Barzee, Suzanne, Snarsky, Victoria, Santucci, Camila, Tran, Brian, Langer, Robert, Zugates, Gregory T., Anderson, Daniel G., Kornbluth, Richard S.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754331/ https://www.ncbi.nlm.nih.gov/pubmed/19812695 http://dx.doi.org/10.1371/journal.pone.0007334

Ejemplares similares

Multimeric forms of 4-1BBL as stimulators of T cells for adoptive immunotherapy
por: Kornbluth, Richard S, et al.
Publicado: (2014)

Multimeric forms of CD40 ligand (CD40L), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L), CD27L/CD70, and other TNFSFs as tools for adoptive cell therapy
por: Kornbluth, Richard S
Publicado: (2013)

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization
por: Zhang, Di, et al.
Publicado: (2017)

Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands
por: Grossmann, Claudius, et al.
Publicado: (2009)

P02-04. Multimeric soluble CD40 ligand efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus strains
por: Najera, J, et al.
Publicado: (2009)

Effects of multimerization on the temporal variability of protein complex abundance
por: Häkkinen, Antti, et al.
Publicado: (2013)

Soluble CD14 Enhances the Response of Periodontal Ligament Stem Cells to Toll-Like Receptor 2 Agonists
por: Behm, Christian, et al.
Publicado: (2019)

Multimerization rules for G-quadruplexes
por: Kolesnikova, Sofia, et al.
Publicado: (2017)

Analysis of Mutant SOD1 Electrophoretic Mobility by Blue Native Gel Electrophoresis; Evidence for Soluble Multimeric Assemblies
por: Brown, Hilda H., et al.
Publicado: (2014)

Toll-Like Receptor 9 Agonists in Cancer
por: Karapetyan, Lilit, et al.
Publicado: (2020)

Breaking symmetry in multimeric ATPase motors
por: Sysoeva, Tatyana A, et al.
Publicado: (2014)

Structure and Function of Multimeric G-Quadruplexes
por: Kolesnikova, Sofia, et al.
Publicado: (2019)

Multimerization variants as potential drivers of neofunctionalization
por: Lee, Youngwoo, et al.
Publicado: (2021)

Detection of Specific RNA Targets by Multimerization
por: Sakhabutdinova, Assol R., et al.
Publicado: (2023)

Toll-Like Receptor Agonists Synergize with CD40L to Induce Either Proliferation or Plasma Cell Differentiation of Mouse B Cells
por: Boeglin, Emmanuelle, et al.
Publicado: (2011)

Protein Scaffold‐Based Multimerization of Soluble ACE2 Efficiently Blocks SARS‐CoV‐2 Infection In Vitro and In Vivo
por: Kayabolen, Alisan, et al.
Publicado: (2022)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

HU multimerization shift controls nucleoid compaction
por: Hammel, Michal, et al.
Publicado: (2016)

Induced Fit in Protein Multimerization: The HFBI Case
por: Riccardi, Laura, et al.
Publicado: (2016)

Modeling the assembly order of multimeric heteroprotein complexes
por: Peterson, Lenna X., et al.
Publicado: (2018)

Improved Cancer Targeting by Multimerizing Aptamers on Nanoscaffolds
por: Omer, Marjan, et al.
Publicado: (2020)

Analysis of multimerization of the SARS coronavirus nucleocapsid protein
por: He, Runtao, et al.
Publicado: (2004)

Designed protein multimerization and polymerization for functionalization of proteins
por: Permana, Dani, et al.
Publicado: (2022)

Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
por: Rolfo, Christian, et al.
Publicado: (2023)

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
por: Carpenter, Erica L, et al.
Publicado: (2009)

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

The Toll-Like Receptor Agonist Imiquimod Is Active against Prions
por: Oumata, Nassima, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Trial Watch: Toll-like receptor agonists in oncological indications
por: Aranda, Fernando, et al.
Publicado: (2014)

Anti-tumor Activity of Toll-Like Receptor 7 Agonists
por: Chi, Huju, et al.
Publicado: (2017)

The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
por: Huang, Lingling, et al.
Publicado: (2022)

CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
por: Bonnans, Caroline, et al.
Publicado: (2020)

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
por: Melssen, Marit M., et al.
Publicado: (2019)

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
por: Ribas, Antoni, et al.
Publicado: (2021)

Optimization of Multimeric Human Papillomavirus L2 Vaccines
por: Jagu, Subhashini, et al.
Publicado: (2013)

Aggregate complexes of HIV-1 induced by multimeric antibodies
por: Stieh, Daniel J, et al.
Publicado: (2014)

Multimerization Increases Tumor Enrichment of Peptide–Photosensitizer Conjugates
por: Zhao, Jisi, et al.
Publicado: (2019)

Formation of multimeric antibodies for self-delivery of active monomers
por: Dekel, Yaron, et al.
Publicado: (2017)

Multimeric RNAs for efficient RNA-based therapeutics and vaccines
por: Kim, Dajeong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_se113rpjik72u9s6st2pqb445k